US$ 22.79
is fda stopping tirzepatide says shortage of GLP-1 drug over is fda stopping compounded tirzepatide
Description
Compounded tirzepatide contains the identical tirzepatide molecule and produces the same clinical outcomes as brand-name formulations

In December 2024 , the FDA issued warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research for selling semaglutide, tirzepatide, and retatrutide as unapproved drugs, part of a major escalating enforcement campaign against grey-market peptide vendors that has resulted in warehouse raids, criminal prosecutions, and multiple vendor shutdowns across 2025 and into 2026
Patients should avoid injecting into areas with active skin conditions, bruising, or scarring
Weight Including Bracket: 26.5 lbs

Journal of Epidemiology

A.KirkpatrickC
